Durakinase Injection 1.5 MIU 1 Vial

 4,388.00

Manufactured by:
Active Pharmaceutical Ingredient:
Drug Strength: 1.5 MIU
Drug Form : Injection
Pack Size : 1 vial

Durakinase Injection contains Streptokinase | belongs to Fibrinolytic

SKU: pg_7011_9630 Category:

Alternate brands of Durakinase Injection 1.5 MIU 1 Vial

Brand Name Price Savings
Unitinase Injection 1.5 MIU 1 Vial  4,370.00 You can save 18
Streptokinase Injection 1.5 MIU 1 Amp  4,738.00 You will pay -350 more
Streptase Injection 1.5 MIU 1 Amp  5,765.00 You will pay -1377 more
Eskinase Injection 1.5 MIU 1 Vial  4,665.78 You will pay -277.78 more
Diclair-ST Injection 1.5 MIU 1 Vial  4,900.00 You will pay -512 more
List of alternate brands

Reviews

There are no reviews yet.

Be the first to review “Durakinase Injection 1.5 MIU 1 Vial”

How it works

This medicine increases the formation of an enzyme (plasmin) which is responsible for the breakdown of blood clots.

Side effects

Major & minor side effects for Durakinase Injection 1.5 MIU 1 Vial

  • Skin Rash severe
  • Flushing severe
  • Skin blistering severe
  • Shortness of breath severe
  • Low blood pressure severe
  • Nosebleed
  • Headache
  • Muscle pain and weakness
  • Diarrhea
  • Chills
  • Dizziness severe

Uses of Durakinase Injection 1.5 MIU 1 Vial

What is it prescribed for?

  • Acute myocardial infarction

    This medicine is used in the treatment and prevention of a myocardial infarction (heart attack). It dissolves blood clots and promotes a smooth flow of blood, thus reducing the strain on the heart.

  • Deep Vein Thrombosis

    This medicine is used in the treatment and prevention of deep vein thrombosis (blood clot in the deep veins of the body).

  • Pulmonary Embolism

    This medicine is used in the treatment and prevention of pulmonary embolism (blood clot in the lung arteries).

  • Arterial thrombosis

    This medicine is used in the treatment and prevention of arterial thrombosis (blood clot in the arteries).

Concerns

Frequently asked questions

  • Onset of action

    On intravenous administration, the onset of action of this medicine is immediate.

  • Duration of Effect

    The effect of this medicine lasts for an average duration of 4 to 12 hours.

  • Safe with Alchohol?

    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

  • Is it habit forming?

    No habit forming tendency has been reported.

  • Usage in pregnancy?

    This medicine is not recommended for use in pregnant women except in life-threatening conditions. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may prescribe a safer alternative based on your clinical condition.

  • Usage while breast-feeding?

    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue breastfeeding for a short period of time, based on your clinical condition. Replacement with a suitable alternative may be necessary in some cases.

When not to use?

  • Internal bleeding

    This medicine is not recommended for use in patients with a known history of active or recent internal bleeding since it may worsen the patient's condition.

  • Intracranial neoplasm

    This medicine is not recommended for use in patients with a known history of an intracranial tumor due to the increased risk of excessive bleeding.

  • Allergy

    This medicine is not recommended for use in patients with a known allergy to Durakinase Injection 1.5 MIU 1 Vial or any other inactive ingredients present along with it.

  • Surgery

    This medicine is not recommended for use in patients with a recent history of intracranial or intraspinal surgery due to the increased risk of excessive bleeding.

  • Uncontrolled blood pressure

    This medicine is not recommended for use in patients with a known history of uncontrolled blood pressure since it may worsen the patient's condition.

  • Head trauma

    This medicine is not recommended for use in patients with a recent history of head trauma due to the increased risk of excessive bleeding.

  • Acute pancreatitis

    This medicine is not recommended for use in patients with a known history of acute pancreatitis since it may worsen the patient's condition.

Warnings

Warnings for special population
  • Pregnancy

    This medicine is not recommended for use in pregnant women except in life-threatening conditions. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may prescribe a safer alternative based on your clinical condition.

  • Breast-feeding

    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue breastfeeding for a short period of time, based on your clinical condition. Replacement with a suitable alternative may be necessary in some cases.

General Warnings
  • Head injury

    This medicine is not recommended for use in patients with a recent history of head injury due to the increased risk of excessive bleeding. Replacement with a suitable alternative should be considered under your doctor's supervision.

  • Bleeding disorders

    This medicine is not recommended for use in patients with a known history of bleeding disorders due to the increased risk of worsening of the patient's condition.

  • Kidney diseases

    This medicine should be used with extreme caution in patients with a known history of kidney diseases due to the increased risk of worsening of the patient's condition. Frequent monitoring of kidney function is recommended for such patients. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition.

  • Hepatic diseases

    This medicine should be used with extreme caution in patients with a known history of hepatic diseases due to the increased risk of worsening of the patient's condition. Frequent monitoring of liver function is recommended for such patients. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition.

  • Cerebrovascular diseases

    This medicine should be used with extreme caution in patients with a known history of cerebrovascular diseases due to the increased risk of worsening of the patient's condition. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition.

  • Surgey

    This medicine is not recommended for use in patients with a recent history of a surgery due to the increased risk of excessive bleeding.

  • High blood pressure

    This medicine should be used with extreme caution in patients with a known history hypertension (high blood pressure) due to the increased risk of worsening of the patient's condition. Frequent monitoring of blood pressure is recommended for such patients. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition.

Dosage

  • Missed Dose

    Since this medicine is administered in the hospital or clinical setting by a qualified healthcare professional, the likelihood of missing a dose is very low.

  • Overdose

    Since this medicine is administered in the hospital or clinical setting by a qualified healthcare professional, the likelihood of an overdose is very low. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.

Interactions

Interaction with Medicines
  • Citalopram moderate
  • Fluoxetine moderate
  • Lisinopril moderate
  • Diclofenac moderate
  • Anticoagulants severe
Disease interactions
  • moderate

    This medicine should be used with caution in patients with lung diseases since it may worsen the patient's condition. Close monitoring of lung function is recommended for such patients. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

  • severe

    This medicine is not recommended for use in patients with bleeding disorders since it may worsen the patient's condition. Replacement with a suitable alternative should be considered under your doctor's supervision.

  • severe

    This medicine is not recommended for use in patients with uncontrolled hypertension since it may worsen the patient's condition. Replacement with a suitable alternative should be considered under your doctor's supervision.

General Instructions

This medicine is administered by a qualified healthcare professional in the clinical or hospital setting. Carefully follow all the instructions given by your doctor. Inform the doctor if you have an allergy to this medicine. Report to the doctor all your current medicines as well as your medical conditions before receiving this medicine.

Other details

  • Usage does not depend on food timings
  • To be taken as instructed by doctor
  • Does not cause sleepiness

References

Additional Information>

How to use Durakinase Injection 1.5 MIU 1 Vial

IM: Do not administer by IM injection. IV: For IV or intra-coronary use only. Infusion pump is required. Use in-line filter gt;0.8 micron. Acute MI: Dilute two 750000 unit vials of streptokinase with 5 mL D5W each, gently swirl to dissolve. Add this dose of the 1.5 million units to 150 mL D5W. This should be infused over 60 min; an in-line filter gt;0.45 micron should be used. Acute pulmonary embolism: Dilute four 750000 unit vials of streptokinase with 5 mL dextrose 5% in water (D5W) each, gently swirl to dissolve. Add this dose of 3 million units to 250 mL D5W, an in-line filter gt; 0.45 micron should be used. Administer 250000 units (23 mL) over 30 min followed by 100000 units /hour (9 mL/hour) for 24 hours. Thrombosis: Administer 250000 units to start, then 100000 units/hour for 24-72 hours depending on location. Cannula occlusion: 250000 units into cannula, clamp for 2 hours then aspirate contents and flush with NS.
Compatibility: Stable in D5W, NS. Incompatible with dextrans.
Stability: Intact vials should be stored at room temperature. Stability of parenteral admixture at room temperature (25°C) is 8 hours and at refrigeration (4°C) is 24 hours. Reconstituted solutions should be refrigerated and are stable for 24 hours.

UNLICENSED USE
Children: Intravascular thrombosis: IV infusion. 1 mth-12 yr, initially 2500-4000 units/kg over 30 minutes, followed by continuous IV infusion of 500-1000 units/kg/hr for up to 3 days until reperfusion occurs; 12-18 yr, initially 250 000 units over 30 minutes, followed by continuous IV infusion of 100000 units/hr for up to 3 days until reperfusion occurs.

what are the adverse effects of Durakinase Injection 1.5 MIU 1 Vial?

Hypotension, arrhythmias. Febrile reactions, anaphylaxis (rare). Haemorrhage. Minor bleeding from puncture sites, severe haemorrhage. Pulmonary oedema. Cholesterol embolism.

What happens if I miss a dose of Durakinase Injection 1.5 MIU 1 Vial?

Adults: Acute myocardial infarction: Single dose of 1.5 million IU by IV infusion over 1 hr.
Dissolution of other thrombi and emboli: Loading dose of 250,000 IU by IV infusion, then 100,000 IU per hr for 24-72 hr, depending on condition; see literature.
Acute pulmonary embolism: 3 million unit dose over 24 hr.

One of the following licensed pharmacy from the nearest location will deliver Durakinase Injection 1.5 MIU 1 Vial. The details of the licensed pharmacy shall be shared once you request the drugs and the respective pharmacy accepts your request based on valid prescription and availability.

Questions and Answers

There are no questions yet. Be the first to ask a question about this product.

Only registered users are eligible to enter questions

Medicalstore.com.pk © All rights reserved

Made with ❤ by Dairah

Shopping Cart